High-dose, high-precision radiation therapy safe, effective for solitary kidney cancer patients with only one kidney
(American Society for Radiation Oncology) Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. Findings will be presented in a news briefing today at 12 p.m. from the American Society for Radiation Oncology (ASTRO) Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

' Revolutionary' Data to Be Presented at ESMO 2018'Revolutionary' Data to Be Presented at ESMO 2018
Evolutions and even revolutions are expected when the latest data in head and neck cancer, renal cell carcinoma, breast cancer, and ovarian cancer are presented at the leading European cancer meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance.10/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 8, 2018 Category: Urology & Nephrology Source Type: news

Differentiating Benign Renal Tumors From Chromophobe RCC
A radiographic measure may help clinicians distinguish between benign renal oncocytoma and chromophobe renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma
The use of robotic tumor enucleation conferred favorable long-term surgical margins and local recurrence rates in patients with sporadic renal cell carcinoma (RCC), according to the results of a single-center Italian study.10/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 4, 2018 Category: Urology & Nephrology Source Type: news

A New Front Line Is Taking Shape in Metastatic Renal Cell Carcinoma
The dismal prognosis for patients with metastatic renal cell carcinoma (mRCC) has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.10/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 4, 2018 Category: Urology & Nephrology Source Type: news

Epidemiology of Renal Cell Carcinoma
Smoking, obesity, hypertension and chronic kidney disease are risk factors for kidney cancer.09/28/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 28, 2018 Category: Urology & Nephrology Source Type: news

Renal Cell Carcinoma Center of Excellence
We invite you to become a member of PracticeUpdate and the Renal Cell Carcinoma Center of Excellence, an expert-curated resource that ’s dedicated to practicing physicians. The Renal Cell Carcinoma Center of Excellence provides physicians with the most up to date information on patient care.09/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 27, 2018 Category: Urology & Nephrology Source Type: news

New nanotherapy offers hope in treating drug-resistant renal cell carcinoma
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.09/26/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 26, 2018 Category: Urology & Nephrology Source Type: news

New nanotherapy offers hope in treating drug-resistant renal cell carcinoma
(Wayne State University - Office of the Vice President for Research) A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2018 Category: International Medicine & Public Health Source Type: news

NLR Predicts Survival After Cytoreductive Nephrectomy+Thrombectomy
Preoperative neutrophil-lymphocyte ratio (NLR) may predict survival following cytoreductive nephrectomy plus thrombectomy for renal cell carcinoma (RCC), a new study suggest.09/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 19, 2018 Category: Urology & Nephrology Source Type: news

10 Healthy Reasons to Eat a Banana Every Day
Researchers found that people who ate lots of fruits and vegetables - more than 75 servings per month, or roughly three servings total per day - had the lowest risk of developing renal cell carcinoma. When researchers looked at fruit specifically, bananas seemed to be the most beneficial due to their high concentration of antioxidants.09/18/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 18, 2018 Category: Urology & Nephrology Source Type: news

Blood Biomarker May Help Identify Those at Increased Risk for RCC
Concentrations of KIM-1 in the blood may predict for renal cell carcinoma up to 5 years prior to diagnosis. (Source: CancerNetwork)
Source: CancerNetwork - August 30, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma
According to the University of Texas, 5-8% of RCC cases are hereditary.08/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2018 Category: Urology & Nephrology Source Type: news

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Although a subset of clear cell renal cell carcinoma (ccRCC) patients respond to immune checkpoint blockade (ICB), predictors of response remain uncertain.08/24/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 24, 2018 Category: Urology & Nephrology Source Type: news

Selecting Patients With Renal Cell Carcinoma for Adjuvant Sunitinib Therapy
Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma (RCC) that should receive adjuvant sunitinib (Sutent) therapy.08/23/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 23, 2018 Category: Urology & Nephrology Source Type: news

Diabetes Can Develop in Cancer Patients Treated With Checkpoint Inhibitors
Cancer treatment has been transformed by the use of monoclonal antibodies (mAbs) that block immune inhibitory ligands CTLA-4 and PD-1, known as immune checkpoint inhibitors (CPIs). With these options for treatment of cancers that are resistant to conventional cancer therapies, the life expectancy of patients with melanoma, lung cancer, renal cell carcinoma, and other cancers, has shown significant improvement. However, according to the journal Diabetes, some patients experience adverse effects. One percent of patients treated with anti –PD-1 or –PD-L1 CPIs develop diabetes.08/22/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 22, 2018 Category: Urology & Nephrology Source Type: news

Case Studies: Treatment of Refractory Metastatic Renal Cell Carcinoma
Thomas Hutson, DO, PharmD, reviews the case of a 70-year old woman who presents with symptomatic, metastatic clear cell renal cell carcinoma.08/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2018 Category: Urology & Nephrology Source Type: news

Case Studies: Perspective on the Treatment of Advanced Renal Cell Cancer
In this video, Dr. Robert J. Motzer discusses the treatment methods he used on a 49-year-old male with recurrent RCC.08/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2018 Category: Urology & Nephrology Source Type: news

VTE Risk May Hurt Survival After Kidney Cancer Surgery
All-cause mortality was significantly higher among renal cell carcinoma (RCC) patients who developed symptomatic venous thromboembolism (VTE) after undergoing nephrectomy and inferior vena cava (IVC) tumor thrombectomy (TT) accompanied by intravascular tumor thrombosis, a retrospective analysis showed.08/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 20, 2018 Category: Urology & Nephrology Source Type: news

Surgery Prevails as Initial Therapy for mRCC
Patients with untreated metastatic renal cell carcinoma (mRCC) had significantly better survival with surgery rather than targeted therapy as the initial treatment, a retrospective review of 15,000 patients showed.08/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 17, 2018 Category: Urology & Nephrology Source Type: news

Blood test could detect kidney cancer up to five years prior to clinical diagnosis
(Beth Israel Deaconess Medical Center) A team of investigators led by Beth Israel Deaconess Medical Center (BIDMC) medical oncologist Rupal Bhatt, M.D., Ph.D., has demonstrated that a molecule called KIM-1, a protein present in the blood of some patients with renal cell carcinoma is present at elevated levels at the time of diagnosis, can also serve as a tool to predict the disease's onset up to five years prior to diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 16, 2018 Category: Cancer & Oncology Source Type: news

Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association
Hypermethylation has been documented in some myeloid disorders including myelodysplastic syndrome (MDS) and in renal cell carcinoma (RCC). A group at the Mayo Clinic noticed the epigenetic marking patterns between these vastly different conditions and wondered if there was a connection. The group found that there was a strong association.08/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 9, 2018 Category: Urology & Nephrology Source Type: news

Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors
Messenger RNA encodes cellular function and phenotype. In the context of human cancer, it defines the identities of malignant cells and the diversity of tumor tissue. We studied 72,501 single-cell transcriptomes of human renal tumors and normal tissue from fetal, pediatric, and adult kidneys. We matched childhood Wilms tumor with specific fetal cell types, thus providing evidence for the hypothesis that Wilms tumor cells are aberrant fetal cells. In adult renal cell carcinoma, we identified a canonical cancer transcriptome that matched a little-known subtype of proximal convoluted tubular cell. Analyses of the tumor compos...
Source: ScienceNOW - August 9, 2018 Category: Science Authors: Young, M. D., Mitchell, T. J., Vieira Braga, F. A., Tran, M. G. B., Stewart, B. J., Ferdinand, J. R., Collord, G., Botting, R. A., Popescu, D.-M., Loudon, K. W., Vento-Tormo, R., Stephenson, E., Cagan, A., Farndon, S. J., Del Castillo Velasco-Herrera, M., Tags: Development, Medicine, Diseases reports Source Type: news

Biomarkers May Predict TKI Response In Metastatic RCC
Angiogenesis-related biomarkers regulated by hypoxia were found to be strong predictors of primary renal tumor response (PRT), progression-free survival (PFS), and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who were being treated with sunitinib prior to kidney removal, according to research published in Clinical Cancer Research.108/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Sunitinib vs Nephrectomy Followed By Sunitinib In Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, M éjean et al found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Results From The Carmena Trial
Arnaud M éjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

VEGF TKI + Immunotherapy Combinations For mRCC
This video discusses strategies for metastatic renal cell carcinoma that involve I-O therapies in combination with VEGF-targeted therapies.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Dr. Drake On The Role of Cytoreductive Nephrectomy In RCC
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia ’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

New Evidence May Help Improve Management Of Rare Kidney Cancers
Researchers have identified relapse patterns of nonclear cell renal cell carcinomas — an understudied group of rare kidney cancers — that are distinct from the more common clear cell renal cell carcinomas. The findings may help improve the management of patients with nonclear cell renal cell carcinomas (non-ccRCC), who represent approximately 20 percent of kidney cancer patien t populations.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Young Mother Has Hope and Health After a New Technique for Treating Kidney Cancer
Twenty-two weeks into her third pregnancy, Jessica Dykstra experienced incredible joy and intense fear --- in just a few minutes. Jessica learned she was having a baby girl to complement her two toddler boys. And just minutes before, the 25-year-old San Diego resident was diagnosed with stage 2 renal cell carcinoma — a malignant tumor on her left kidney.08/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 7, 2018 Category: Urology & Nephrology Source Type: news

Cytoreductive Nephrectomy May Still Remain Standard For Some With Metastatic Renal Cell Carcinoma
The addition of cytoreductive nephrectomy to treatment with sunitinib malate did not provide a survival benefit for intermediate and poor-risk patients with metastatic renal cell carcinoma, according to results of the phase 3 CARMENA clinical trial presented at ASCO Annual Meeting.08/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 6, 2018 Category: Urology & Nephrology Source Type: news

Certain Renal Cancer Subtypes Linked to Obesity
Obesity is associated with development of clear cell and possibly chromophobe renal cell carcinoma (RCC), but not papillary RCC, according to researchers.07/31/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 31, 2018 Category: Urology & Nephrology Source Type: news

Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma
Progesterone receptor membrane component 1 (PGRMC1) and Na+/K+ ‑ATPase α1 subunit (ATP1A1) are two proteins associated with the clinical prognosis of renal cell carcinoma (RCC) and RCC cell proliferation. However, the two proteins have been previously studied independently, and their combined influence on the clinical outcome of RCC remains unclear.07/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 27, 2018 Category: Urology & Nephrology Source Type: news

Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies
Targeted therapies, in particular antiangiogenic therapies (AATs), have become the standard of treatment for metastatic renal cell carcinoma (mRCC). Although common adverse effects like fatigue have been well-established, sexual disorders induced by these treatments, although often reported, have been poorly evaluated.07/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 27, 2018 Category: Urology & Nephrology Source Type: news

Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis
Treatment of patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD) on dialysis poses a therapeutic challenge, particularly as this patient group was excluded from the pivotal clinical trials. In addition, there is uncertainty regarding drug dosing/pharmacokinetics, lack of safety and efficacy data, and potential for increased toxicity when using targeted therapy or immunotherapy for the management of patients with mRCC on dialysis.07/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 25, 2018 Category: Urology & Nephrology Source Type: news

Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is the main subtype of malignant kidney cancer. Long non ‑coding RNA (lncRNA) serves a key role in predicting survival in patients with cancer.07/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 25, 2018 Category: Urology & Nephrology Source Type: news

VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
Studies show that ZHX2 could be used as a potential therapeutic target for ccRCC.07/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 23, 2018 Category: Urology & Nephrology Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Renal cell cancer risk after kidney transplantation
This study shows the risk of RCC after kidney transplantation.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma
In a study reported in JAMA Oncology, Carlo et al found a high prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma (RCC).07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Acute Kidney Injury in Patients With Cancer
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Discovery of kidney cancer driver could lead to new treatment strategy
(UNC Lineberger Comprehensive Cancer Center) In a study published in the journal Science, researchers suggest that ZHX2 is a potential new therapeutic target for clear cell renal cell carcinoma, which is the most common type of kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2018 Category: International Medicine & Public Health Source Type: news

VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
Inactivation of the von Hippel-Lindau (VHL) E3 ubiquitin ligase protein is a hallmark of clear cell renal cell carcinoma (ccRCC). Identifying how pathways affected by VHL loss contribute to ccRCC remains challenging. We used a genome-wide in vitro expression strategy to identify proteins that bind VHL when hydroxylated. Zinc fingers and homeoboxes 2 (ZHX2) was found as a VHL target, and its hydroxylation allowed VHL to regulate its protein stability. Tumor cells from ccRCC patients with VHL loss-of-function mutations usually had increased abundance and nuclear localization of ZHX2. Functionally, depletion of ZHX2 inhibited...
Source: ScienceNOW - July 19, 2018 Category: Science Authors: Zhang, J., Wu, T., Simon, J., Takada, M., Saito, R., Fan, C., Liu, X.-D., Jonasch, E., Xie, L., Chen, X., Yao, X., Teh, B. T., Tan, P., Zheng, X., Li, M., Lawrence, C., Fan, J., Geng, J., Liu, X., Hu, L., Wang, J., Liao, C., Hong, K., Zurlo, G., Parker, J Tags: Cell Biology, Medicine, Diseases reports Source Type: news

Better Metastatic Renal Cell Carcinoma Survival at Higher-Volume Facilities Better Metastatic Renal Cell Carcinoma Survival at Higher-Volume Facilities
Patients with metastatic renal cell carcinoma (mRCC) treated at higher-volume facilities survive longer than those treated at lower-volume facilities, according to a registry-based analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 16, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

A Call for Better Screening for Hereditary Renal Cell Carcinoma
It may be time to adopt a broader approach to tumor and matched normal sequencing in patients with advanced renal cell carcinoma (RCC), according to a large new study.07/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 13, 2018 Category: Urology & Nephrology Source Type: news

Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic
Anastomosing hemangioma (ah) is a rare subtype of primary vascular tumour that can, clinically and radiologically, present similarly to malignant renal tumours such as renal cell carcinoma (rcc) and angiosarcoma.07/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 12, 2018 Category: Urology & Nephrology Source Type: news

A Call for Better Screening for Hereditary Renal Cell Carcinoma
More than 20% of patients with non –clear cell RCC had a germline mutation, and half of this group could benefit from direct systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - July 12, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Targeting tumor-associated acidity in cancer immunotherapy
Checkpoint inhibitors, such as cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) monoclonal antibodies have changed profoundly the treatment of melanoma, renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and bladder cancer. Currently, they are tested in various tumor entities as monotherapy or in combination with chemotherapies or targeted therapies. However, only a subgroup of patients benefit from checkpoint blockade (combinations).07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 11, 2018 Category: Urology & Nephrology Source Type: news

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma
In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib07/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news